北陸藥業(300016.SZ):與醫未醫療未來將全面整合資源,尋找深度業務合作的契機
格隆匯6月15日丨北陸藥業(300016.SZ)近期在接待機構調研時表示,醫未醫療是中國腦部疾病精準診療的領導者,也是首家專注腦部疾病超早期篩查和精準診療的腦科學人工智能AI企業。其核心產品主要聚焦阿爾茨海默病、腦卒中、兒童發育障礙的精準篩查、診斷和康復治療,是國內較全面覆蓋腦部疾病診療全流程的數字產品公司。現已領先行業完成多個腦部疾病不同功能模塊的NMPA、CE、FDA認證等。
公司與醫未醫療未來將全面整合資源,尋找深度業務合作的契機,實現協同發展,打開全新的業務領域。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.